We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Combined MRI-Optics Technique Provides Breast Cancer Diagnosis

By Biotechdaily staff writers
Posted on 30 Apr 2007
By combining two techniques, magnetic resonance imaging (MRI) and near-infrared optics, researchers may have designed a new, potentially more effective method for diagnosing breast cancer. More...


The new technique utilizes MRI to produce an image of the breast, providing information on its structure, including shape and composition. The near-infrared light technique provides data on how the tissue is functioning, such as, whether a region contains a large amount of blood and is rapidly consuming oxygen as early tumors typically do. The researchers, from Dartmouth College Medical School (Hanover, NH, USA), are hoping this dual-procedure approach will be a vital application to learning which tissues are malignant before performing a biopsy. Their pilot study, demonstrating the feasibility of the concept, was published in the April 15, 2007, issue of the journal Optics Letters.

The pilot study involved a 29-year-old woman with a ductal carcinoma, a very common breast tumor, in her left breast. A contrast-enhanced MRI procedure was performed, where MRI was performed before and after the contrasting agent gadolinium was injected. The area enhanced by the contrasting agent was targeted for the optical technique, known as near-infrared spectroscopy (NIRS). The study's findings showed the area's hemoglobin level was high, oxygen saturation was low, and water content was high, all indicators of cancerous tissue.

Recent developments in medical imaging systems have focused on increasing the detail of anatomic images, but there has also been a growing interest in devices that provide information on tissue function. One of the difficulties with functional imaging has been that most of these devices have low spatial resolution. The structural information from the MR image helps guide the NIRS technique to the regions of interest so that the two can together create high-resolution, functional images of breast cancer.

Mammograms are much less costly than MRI, but because they compress the breast to show all of the information in one view, they are less effective of a tool, particularly when the breast is dense. MRI provides multiple slices of high-resolution images of breast tissue, creating a three-dimensional image. Unlike mammography, the NIRS technique does not generate images directly from the data acquired by the machine. It records the spectrum of near-infrared light that is absorbed or scattered (bounced around) in the tissue.

If larger studies prove to be successful, and the U.S. Food and Drug Administration (FDA) considers the procedure valuable enough for insurance reimbursement, Dr. Paulsen reported that this new method could become more widely available within the next five years.


Related Links:
Dartmouth College Medical School

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.